Key result
Antithrombotic therapy shows no significant effect on colonoscopy polyp detection rates versus no treatment.
Why the study?
Does antithrombotic therapy affect polyp detection rate and prevalence of non-neoplastic findings in FIT-positive patients undergoing colonoscopy?
Cohort (n=26,280)
Yes
Does antithrombotic therapy affect polyp detection rate and prevalence of non-neoplastic findings in FIT-positive patients undergoing colonoscopy?
Answers are grounded in this paper and cite their sources.
Demographic confounding, rather than antithrombotic therapy, explains the crude associations in colonoscopy outcomes, supporting the continued use of antithrombotics during CRC screening.
OBJECTIVE: Faecal immunochemical test (FIT) is widely used in colorectal cancer (CRC) screening, but the impact of antithrombotic therapy on colonoscopy outcomes remains unclear. This study aimed to compare polyp detection rate (PDR) and prevalence of non-neoplastic findings in FIT-positive patients undergoing colonoscopy, stratified by antithrombotic therapy. METHODS: We conducted a retrospective, multicentre cohort study of 26 280 FIT-positive colonoscopies performed between 2016 and 2023 across seven gastroenterology centres in Israel. The FIT positivity threshold was 75 ng/mL. Patients were grouped by therapy: antiplatelets (n=1904), anticoagulants (n=262) or no antithrombotic treatment (n=24 079). Using crude and matched analyses, we assessed PDR, adenoma detection rate (ADR), CRC detection and diverticulosis prevalence. RESULTS: Patients on antithrombotics were older (mean 65.9±7 vs 61.0±8 years; p<0.001), more often men (65.2% vs 50.1%; p<0.001) and had higher comorbidity rates. Crude PDR was higher in antithrombotic users (55.5% vs 51.9%; p=0.001), but ADR was similar (28.2% vs 28.3%; p=0.950). Diverticulosis was more prevalent in the antithrombotic group (24.0% vs 17.4%; p<0.001). After matching for age and sex (n=2201 pairs), all previously significant associations were eliminated: PDR were no longer different (55.5% vs 53.1%; p=0.112), diverticulosis prevalence became identical (24.0% vs 24.3%; p=0.799) and normal colonoscopy rates were similar (27.5% vs 29.6%; p=0.123). ADRs remained comparable (28.2% vs 26.7%; p=0.269), and CRC detection rates were identical (2.0% vs 2.0%; p=0.998). CONCLUSION: Demographic confounding, rather than antithrombotic therapy per se, explains the crude associations in colonoscopy outcomes. The matched analysis demonstrates that antithrombotics do not independently affect polyp detection, diverticulosis prevalence or adenoma detection when age and sex are controlled for. These findings support the continued use of antithrombotics during CRC screening, shifting clinical interpretation from medication-based to demographic-based risk stratification.
No takes yet. Share an insight, caveat, or question.
Abu‐Freha et al. (2025) conducted a cohort in Colorectal cancer screening (FIT-positive) (n=26,280). Antithrombotic therapy vs. No antithrombotic treatment was evaluated on Polyp detection rate (matched analysis) (p=0.112). After matching for age and sex, antithrombotic therapy did not affect the polyp detection rate during colonoscopy compared to no treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: